Article
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Cell reports - 11 Sept 2014
Lamba Simona, Russo Mariangela, Sun Chong, Lazzari Luca, Cancelliere Carlotta, Grernrum Wipawadee, Lieftink Cor, Bernards Rene, Di Nicolantonio Federica, Bardelli Alberto
Abstract excerpt
KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are available to treat KRAS mutant cancers. We used two independent reverse genetic approaches to identify components of the RAS-signaling pathways required for growth of KRAS mutant tumors. Small interfering RNA (siRN...
Topics
- Antineoplastic Agents
- Apoptosis
- Benzimidazoles
- Cell Line, Tumor
- Colorectal Neoplasms
- Humans
- MAP Kinase Signaling System
- Mitogen-Activated Protein Kinase Kinases
- Mutation
- Protein Kinase Inhibitors
- Protein Multimerization